• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SULINDAC Drug Record

  • Summary
  • Interactions
  • Claims
  • SULINDAC chembl:CHEMBL15770 ApprovedAntineoplastic

    Alternate Names:

    CLINORIL
    MK-231
    SULINDAC
    CIS-5-FLUORO-2-METHYL-1-((P-METHYLSULFINYL)BENZYLIDENE)INDENE-3-ACETIC ACID
    CIS-5-FLUORO-2-METHYL-1-((4-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
    SULINDACUM
    (Z)-5-FLUORO-2-METHYL-1-((P-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
    SULINDACO
    CLINORIL®
    chembl:CHEMBL15770
    pubchem.compound:1548887
    rxcui:10237
    chemidplus:38194-50-2
    drugbank:00605

    Drug Info:

    Drug Class anti-inflammatory agents, non-steroidal
    Year of Approval 1978
    FDA Approval 1978
    Drug Class small molecule
    Drug Indications NSAID
    (6 More Sources)

    Publications:

    Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.
    Yip-Schneider et al., 2000, Cyclooxygenase-2 expression in human pancreatic adenocarcinomas., Carcinogenesis
    Fosslien, 2000, Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia., Crit Rev Clin Lab Sci
    Taylor et al., 2000, Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells., Cancer Res.
    Molina et al., 1999, Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs., Cancer Res.
    Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis
    Koornstra et al., 2005, Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients., Cancer Epidemiol. Biomarkers Prev.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Lim et al., 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines., Biochem. Pharmacol.
    Cheng et al., 2003, Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)., Eur. J. Pharmacol.
    Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.
    Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.
    Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem
    Ferner et al., 1991, The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A., Br J Clin Pharmacol
    van der Sloot et al., 1995, Sulindac in established experimental diabetes: a follow-up study., Can J Neurol Sci
    Sharma et al., Topical sulindac therapy in diabetic senile cataracts: cataract-IV., Indian J Ophthalmol
    Jacobson et al., 1983, Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors., Invest. Ophthalmol. Vis. Sci.
    Chaudhry et al., 1983, Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin., Biochem. Pharmacol.
    Crabbe et al., 1985, The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity., Ophthalmic Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Yip-Schneider et al., Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac., J. Gastrointest. Surg.
    Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
    Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.
    Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
    Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.
  • SULINDAC   AKR1B1

    Interaction Score: 2.67

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    8529171 2632448 6413448 6409111 3920599 11752352


    Sources:
    TTD

  • SULINDAC   TNFRSF10A

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16030090


    Sources:
    NCI

  • SULINDAC   PTGS1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    10372826 10484067 12586211 10626810 12512695


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • SULINDAC   FMO3

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SULINDAC   APC

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    19755659


    Sources:
    JAX-CKB

  • SULINDAC   PTGS2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    10372826 10657949 11078056 11118042 10485483


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • SULINDAC   TAC1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1707646


    Sources:
    NCI

  • SULINDAC   BIRC5

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16950207 16707021


    Sources:
    NCI

  • SULINDAC   MYC

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12414619


    Sources:
    NCI

  • SULINDAC   PIK3CA

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12654560 30683736


    Sources:
    NCI CIViC

  • SULINDAC   RXRA

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    23434637


    Sources:
    DTC

  • SULINDAC   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   KDM4E

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SULINDAC   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: SULINDAC

    • Version: 01-August-2011

    Alternate Names:
    SULINDAC Primary Drug Name

    Drug Info:
    Year of Approval 1978
    Drug Class anti-inflammatory agents, non-steroidal

    Publications:

  • TdgClinicalTrial: SULINDAC

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications NSAID
    Drug Class small molecule
    FDA Approval 1978

    Publications:

  • NCI: SULINDAC

    • Version: 14-September-2017

    Alternate Names:
    C850 NCI drug code

    Drug Info:

    Publications:
    Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
    Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.
    Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.

  • DTC: SULINDAC

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL15770 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

  • JAX-CKB: Sulindac

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis

  • CIViC: SULINDAC

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

  • TTD: Sulindac

    • Version: 2020.06.01

    Alternate Names:
    D0Z5IU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL15770

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL15770

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: sulindac

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21